Literature DB >> 24874759

A systematic review of community opioid overdose prevention and naloxone distribution programs.

Angela K Clark1, Christine M Wilder, Erin L Winstanley.   

Abstract

Community-based opioid overdose prevention programs (OOPPs) that include the distribution of naloxone have increased in response to alarmingly high overdose rates in recent years. This systematic review describes the current state of the literature on OOPPs, with particular focus on the effectiveness of these programs. We used systematic search criteria to identify relevant articles, which we abstracted and assigned a quality assessment score. Nineteen articles evaluating OOPPs met the search criteria for this systematic review. Principal findings included participant demographics, the number of naloxone administrations, percentage of survival in overdose victims receiving naloxone, post-naloxone administration outcome measures, OOPP characteristics, changes in knowledge pertaining to overdose responses, and barriers to naloxone administration during overdose responses. The current evidence from nonrandomized studies suggests that bystanders (mostly opioid users) can and will use naloxone to reverse opioid overdoses when properly trained, and that this training can be done successfully through OOPPs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24874759     DOI: 10.1097/ADM.0000000000000034

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  140 in total

1.  Management of Opioid Misuse and Opioid Use Disorders Among Youth.

Authors:  Camille A Robinson; J Deanna Wilson
Journal:  Pediatrics       Date:  2020-05       Impact factor: 7.124

Review 2.  Naloxone dosage for opioid reversal: current evidence and clinical implications.

Authors:  Rachael Rzasa Lynn; J L Galinkin
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

3.  Disparity in naloxone administration by emergency medical service providers and the burden of drug overdose in US rural communities.

Authors:  Mark Faul; Michael W Dailey; David E Sugerman; Scott M Sasser; Benjamin Levy; Len J Paulozzi
Journal:  Am J Public Health       Date:  2015-04-23       Impact factor: 9.308

Review 4.  Harm reduction for young people who use prescription opioids extra-medically: Obstacles and opportunities.

Authors:  Brandon D L Marshall; Traci C Green; Jesse L Yedinak; Scott E Hadland
Journal:  Int J Drug Policy       Date:  2016-02-04

5.  Injection drug use and overdose among young adults who use prescription opioids non-medically.

Authors:  Elliott J Liebling; Traci C Green; Scott E Hadland; Brandon D L Marshall
Journal:  Addict Behav       Date:  2017-07-18       Impact factor: 3.913

6.  Why are some people who have received overdose education and naloxone reticent to call Emergency Medical Services in the event of overdose?

Authors:  Stephen Koester; Shane R Mueller; Lisa Raville; Sig Langegger; Ingrid A Binswanger
Journal:  Int J Drug Policy       Date:  2017-07-19

7.  Association Between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose.

Authors:  Rahi Abouk; Rosalie Liccardo Pacula; David Powell
Journal:  JAMA Intern Med       Date:  2019-06-01       Impact factor: 21.873

8.  Predictors of participant engagement and naloxone utilization in a community-based naloxone distribution program.

Authors:  Christopher Rowe; Glenn-Milo Santos; Eric Vittinghoff; Eliza Wheeler; Peter Davidson; Philip O Coffin
Journal:  Addiction       Date:  2015-08       Impact factor: 6.526

9.  Perceptions about fentanyl-adulterated heroin and overdose risk reduction behaviors among persons seeking treatment for heroin use.

Authors:  Michael D Stein; Shannon R Kenney; Bradley J Anderson; Genie L Bailey
Journal:  J Subst Abuse Treat       Date:  2019-07-13

10.  Location of fatal prescription opioid-related deaths in 12 states, 2008-2010: Implications for prevention programs.

Authors:  Keith W Easterling; Karin A Mack; Christopher M Jones
Journal:  J Safety Res       Date:  2016-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.